DOSSIER · 13F-HR · Q2 2026

Pivotal bioVenture Partners Investment Advisor LLC

$308M in tracked AUM across 13 positions as of Q2 2026.

PB
CIK 0001844645 · last filed Jun 30, 2026
Total AUM
$308M
as of Q2 2026
Holdings
13
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of SEC 13F Filing: Pivotal bioVenture Partners Investment Advisor LLC
Portfolio Overview

Pivotal bioVenture Partners Investment Advisor LLC manages a highly concentrated portfolio valued at $172.48 million as of September 30, 2025. The firm exhibits a high-conviction investment strategy, holding only 9 positions despite the substantial assets under management. The portfolio experienced positive growth, increasing in value by 6.9% (from $161.34M in the pre...

The fund demonstrates a distinct lack of diversification in the traditional sense, with a heavy emphasis on specific high-growth names. The top three holdings alone account for approximately 75.3% of the total portfolio value. This structure suggests the firm operates as a specialist fund, likely leveraging deep domain expertise to pick winners in a specific niche rather than spreading risk across a broad market index.

Key Holdings

The portfolio is dominated by three core positions, which serve as the primary drivers of performance:

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PCVX
VAXCYTE INC
$83M1.4M26.9%
02
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$33M1.3M10.8%
03
TRVI
TREVI THERAPEUTICS INC
$33M1.7M10.6%
04
AVLN
AVALYN PHARMACEUTICALS INC
$32M967K10.3%
05
EVMN
EVOMMUNE INC
$26M1.9M8.3%
06
MPLT
MAPLIGHT THERAPEUTICS INC
$22M611K7.1%
07
H5870P102
OCULIS HOLDING AG
$21M1.5M6.8%
08
BIOA
BIOAGE LABS INC
$16M653K5.2%
09
IMNM
IMMUNOME INC
$16M733K5.0%
10
ZBIO
ZENAS BIOPHARMA INC
$12M491K4.0%

Filing history

2026Q2Jun 30
$308M 10.0%
13 positionsView →
2026Q1Mar 31
$280M 8.2%
13 positionsView →
2025Q4Dec 31
$259M 50.0%
12 positionsView →
2025Q3Sep 30
$172M 6.9%
9 positionsView →
2025Q2Jun 30
$161M 32.4%
12 positionsLocked
2025Q1Mar 31
$122M 17.7%
9 positionsLocked
2024Q4Dec 31
$148M 12.1%
11 positionsLocked
2024Q3Sep 30
$168M 29.5%
11 positionsLocked
2024Q2Jun 30
$130M 16.4%
10 positionsLocked
2024Q1Mar 31
$156M 60.5%
11 positionsLocked
2023Q4Dec 31
$394M 57.2%
13 positionsLocked
2023Q3Sep 30
$251M 17.3%
13 positionsLocked
Showing 12 of 23